AFT PHARMACEUTICALS LIMITED

(AFT Pharmaceuticals or the Company)

Regulatory and Product Development Oversight Committee Charter

The Regulatory and Product Development Oversight Committee shall be a committee of the board of AFT Pharmaceuticals (the **Board**).

1. **Purpose**

The purpose of the Regulatory and Product Development Oversight Committee is to assist the Board in fulfilling its responsibilities relating to:

(a) the oversight of the Company's regulatory risk management framework and the progress and costs of the Company's key clinical and product development projects; and

(b) the Company's product labelling system, to ensure that the Company is up to date with current and on-going regulatory and clinical knowledge.

2. **Duties and responsibilities**

In addition to any other duties and responsibilities which are assigned to it from time to time by the Board, the Regulatory and Product Development Oversight Committee has the duty and responsibility to:

(a) review, monitor and make recommendations to the Board on the Company's regulatory risk management framework and the progress and costs of the Company's key clinical and product development projects;

(b) review and monitor the Company's quality objectives to assess the suitability and effectiveness of the Company's quality assurance programme; and

(c) receive and monitor reports indicating the Company's compliance with applicable regulations regarding the sale and distribution of pharmaceutical products.

3. **Membership**

Members of the Regulatory and Product Development Oversight Committee shall be appointed by the Board and shall comprise a minimum of three members.

All of the members of the Regulatory and Product Development Oversight Committee shall be directors of AFT Pharmaceuticals.

The Board shall appoint a chairperson for the Regulatory and Product Development Oversight Committee from among the members of the Regulatory and Product Development Oversight Committee**.** The chairperson shall be independent and shall not be the chairperson of the Board.

The appointment and removal of the Regulatory and Product Development Oversight Committee members shall be the responsibility of the Board.

AFT Pharmaceuticals shall identify the members of the Regulatory and Product Development Oversight Committee each year in its annual report.

4. **Meetings**

The Regulatory and Product Development Oversight Committee shall meet as frequently as required.

A quorum of members of the Regulatory and Product Development Oversight Committee shall be a majority of its members.

The Regulatory and Product Development Oversight Committee may have in attendance such members of management and such other persons including external advisers, as it considers necessary to provide appropriate information and advice.

Reasonable notice of meetings and the business to be conducted shall be given to the members of the Regulatory and Product Development Oversight Committee and all other attendees of meetings.

The Regulatory and Product Development Oversight Committee will have direct communication with and unrestricted access to management, employees, external consultants and advisers.

Minutes of all meetings shall be kept.

5. **Review of the Regulatory and Product Development Oversight Committee**

The Regulatory and Product Development Oversight Committee will undertake an annual self-review of its duties and responsibilities. It shall recommend to the Board any suggested changes in the duties and responsibilities of the Regulatory and Product Development Oversight Committee.

6. **Reporting Procedures**

The chairperson of the Regulatory and Product Development Oversight Committee will report to the Board on the Regulatory and Product Development Oversight Committee's proceedings following each meeting on matters relevant to the Regulatory and Product Development Oversight Committee's duties and responsibilities.

The minutes of all Regulatory and Product Development Oversight Committee meetings will be available to members of the Board on request. Extracts from the minutes will be made available to such other persons as the Committee or Board directs, as may be necessary to enable them to properly carry out their functions.

7. **Charter review**

The Board will review this Charter at least annually.

Last updated: April 2022

Last reviewed: April 2023